ViiV Publikationen vom IAS Kongress 2026
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
High acceptability and persistence of long-acting injectable cabotegravir/rilpivirine treatment in Australian primary care: early real-world implementation data from people living with HIV and healthcare workers* B. Eu et al. - In-person poster exhibition |
|
|
Real-world acceptability and experiences of long-acting injectable cabotegravir and rilpivirine: client perspectives and experiences* K.Alford et al. - In-person poster exhibition |
|
|
Acceptability and experience of long-acting injectable cabotegravir and rilpivirine in people with HIV and cognitive impairment* K.Alford et al. - In-person poster exhibition |
|
|
Comparable virologic effectiveness with long-acting cabotegravir + rilpivirine vs. daily bictegravir/emtricitabine/tenofovir alafenamide in the US-based OPERA Cohort Ricky K. Hsu et al. - In-person poster exhibition |
|
|
Resuppression and resistance after confirmed virologic failure among women on CAB+RPV LA in the OPERA Cohort Jessica Altamirano et al. - In-person poster exhibition |
|
|
High virologic suppression among individuals on cabotegravir + rilpivirine long-acting with viral loads ≥50 copies/mL regardless of body mass index in the OPERA Cohort Carl Millner et al. - In-person poster exhibition |
|
|
DTG/3TC-based regimens |
|
|
In VOGUE: DTG/3TC 2-drug regimen is non-inferior to BIC/FTC/TAF 3-drug regimen in a randomized trial in adults with HIV naive to treatment Jade Ghosn et al. - Oral presentation |
|
|
Long-term efficacy, safety and persistence of dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults-results from the 144-week observational extension phase of the DYAD study* Charlotte-Paige Rolle et al. - In-person poster exhibition |
|
|
Incidence and outcomes of AIDS-defining illnesses after dolutegravir/lamivudine initiation in advanced HIV in the DOLCE Study* Pedro Cahn et al. - In-person poster exhibition |
|
|
No reactivation of Hepatitis B in African patients on a tenofovir free regimen for the treatment of HIV: results from the switch to DTG/3TC (Sungura) study* Loice Achieng Ombajo et al. - In-person poster exhibition |
|
|
The body composition signature of switching to BIC/FTC/TAF or DTG/3TC over 96 weeks* S. Di Gregorio et al. - Oral Presentation |
|
|
The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through Week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study* Ruolan Wang et al. - Oral Presentation |
|
|
Who’s in VOGUE: a head‑to‑head clinical trial of dolutegravir/lamivudine (DTG/3TC) versus bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in adults naive to antiretroviral therapy (ART), including those with high viral loads Federico Pulido et al. - In-person poster exhibition |
|
|
Pooled analysis of on-study viremic events (VEs) and outcomes for dolutegravir + lamivudine (DTG+3TC) and comparator 3-drug regimens (3DRs) in clinical trials of people with HIV-1 Pedro Cahn et al. - In-person poster exhibition |
|
|
Pipeline |
|
|
Participants report positive experiences switching from subcutaneous to intravenous lotivibart (LVB, N6LS, VH3810109) and cabotegravir long-acting injections for HIV-1 treatment in EMBRACE study Cassidy Gutner et al. - In-person poster exhibition |
|
|
Other HIV-related data |
|
|
Complex support needs, adherence challenges and interest in long-acting HIV treatment among Trans, Non-Binary, and Gender-Diverse people living with HIV: findings from the coproduced ‘Ask Us Europe’ survey* M. Devonald et al. - In-person poster exhibition |
|
|
Interest of people living with HIV in Europe in future long-acting modalities: Ask Us Europe results* M. Devonald et al. - In-person poster exhibition |
|
*denotes ViiV-supported investigator led and collaborative studies
Diese Seite weiter empfehlen